About Us

Coalition Leadership

Gregory H. Reaman, MD
Chair, Children’s Oncology Group

Gregory H. Reaman, MD, is the first group chair of the Children’s Oncology Group (COG). The COG was formed in March 2000 by the merger of 4 legacy pediatric cancer research organizations and is comprised of over 230 member institutions, responsible for the treatment of 90% of children with cancer in North America.

Dr Reaman is a professor of pediatrics at The George Washington University School of Medicine and Health Sciences and a member of the division of Hematology-Oncology at the Children’s National Medical Center in Washington, DC, which he directed for 17 years. Dr Reaman is a graduate of Loyola University Chicago-Stritch School of Medicine, and completed his pediatrics training at McGill University/The Montreal Children’s Hospital. His postgraduate training in oncology was obtained at the Pediatric Oncology Branch of the National Cancer Institute, where he served as an investigator prior to coming to Children’s Hospital, and where he continues as a consultant.

Dr Reaman serves or has served on the Editorial Boards of Leukemia, Journal of Clinical Oncology, Journal of Pediatric Hematology/Oncology, Pediatric Blood and Cancer, The Oncologist, Cancer, and Physicians Data Query, National Cancer Institute, as well as www.PLWC.org (People Living with Cancer). He has served as an associate editor of Cancer and currently serves as associate editor of Leukemia and Lymphoma. He holds the position as the executive vice president for Medical and Scientific Affairs for the National Childhood Cancer Foundation and is a member of its Board of Trustees. Previously, he served on the Board of Directors of the American Cancer Society and chaired its Task Force on Children and Cancer.

In addition, Dr Reaman serves on the Board of Directors of the American Society of Clinical Oncology’s (ASCO) Patient Education Committee and the Educational Program Committee, and is the Chair of the ASCO Membership Committee. He is a member of the Alliance for Childhood Cancer, a member of the Data Safety Monitoring Board of the National Cancer Institute’s Clinical Oncology Program, and was a member of the Food and Drug Administration’s Oncologic Drugs Advisory Committee; he currently chairs its Pediatric Subcommittee. Dr Reaman is the author of more than 200 peer-reviewed manuscripts.